Loading...

scPharmaceuticals Inc.

SCPH•NASDAQ
HealthcareBiotechnology
$3.52
$0.30(9.32%)

scPharmaceuticals Inc. (SCPH) Stock Overview

Explore scPharmaceuticals Inc.’s financial performance, market position, analyst ratings, and future outlook.

Revenue Growth
167.28%
↑ 167.28%
Profit Growth
$-1.69
↓ 55.35%
EPS Growth
$-1.69
↓ 34.51%
Operating Margin
-158.82%
↓ 16.93%
ROE
-754.13%
↓ 55.35%
Dividend Yield
0.00%

Analyst Recommendations

Strong Buy
0
Buy
2
Hold
0
Sell
0
Strong Sell
0

Price Targets

Low$13.00
Average$13.00
High$13.00

Company Profile

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. for development of single use SmartDose device. scPharmaceuticals Inc. was incorporated in 2013 and is headquartered in Burlington, Massachusetts.

CEO

Mr. John H. Tucker

Employees

162

Headquarters

2400 District Avenue, Burlington, MA

Founded

2017

Frequently Asked Questions

Meyka LogoMeyka

Meyka is the best Alternative Data platform powered by AI providing research insights for investors

Connect With Us

Legal

Resources

Market

Legal Disclaimer

The information provided by Meyka AI PTY LTD is for informational and research purposes only and does not constitute financial, investment, or trading advice. Meyka is a research platform, not a financial advisory service. Investing in financial markets involves risks, and past performance does not guarantee future results. Users should conduct their own due diligence, consult with professional financial advisors, and assess their risk tolerance before making investment decisions. Meyka and its operators are not liable for any financial losses incurred from the use of information on this platform. The data provided is derived from publicly available sources and is believed to be reliable but may not always be accurate or up to date. Users should independently verify information and not rely solely on Meyka for financial decisions. By using Meyka, you acknowledge that it does not provide financial advice or recommendations and agree to seek guidance from a qualified financial professional before making any investment decisions.

© 2025 Meyka AI PTY LTD. All rights reserved.